Scientific Publications
2025
Najm, P., et al. (2025). TK-6302, a supercharged PRAME TCR-T cell therapy containing a high affinity TCR, an activating CD8 coreceptor (costimCD8 CoR) and a FAS-based switch receptor, drives sustained anti-tumor responses. American Association for Cancer Research (AACR) Annual Meeting.
Najm, P., et al. (2025). Optimal activation of TCR-T cells in solid tumors through addition of best-in-class single chain CD8 coreceptors results in CD4 engagement and improved T cell fitness and persistence. American Association for Cancer Research (AACR) Annual Meeting.
Najm, P., et al. (2025). Combined targeting of cancer cells and tumor stroma by engineering dual-specific T cells expressing a TCR and a CAR. American Association for Cancer Research (AACR) Annual Meeting.
Walcher, L., et al. (2025). MyT™ platform-identified PRAME TCRs for T cell therapy demonstrate superior efficacy and best-in-class potential compared to clinical benchmarks. American Association for Cancer Research (AACR) Annual Meeting.
Twyffels, L., et al. (2025). A FAS-based switch receptor tailored to PRAME positive cancer indications, engineered to boost T cell engraftment, and anti-tumor activity. American Association for Cancer Research (AACR) Annual Meeting.
2024
Chen XT, Leisegang M, Gavvovidis I, Pollack SM, Lorenz FKM, Schumacher TN, Daumke O, Blankenstein T. Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system. Front Immunol. 2024 Dec 24;15:1524629. doi: 10.3389/fimmu.2024.1524629. PMID: 39776913; PMCID: PMC11703889.
2023
Walcher, L., et al. (2023). High-affinity PRAME TCRs synergize with tailored CD8 co-receptor and switch receptors to generate potential best-in-class PRAME-targeting TCR-T therapy. Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Knipping, F., et al. (2023). Counteracting TCR-T cell dysfunction in solid tumors through combination of FAS-based switch receptors and CD8 co-receptor. Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Immisch, L., et al. (2023). T-knife’s MyT™ platform for unbiased discovery of most abundant and immunogenic T-cell epitopes. Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Najm, P., et al. (2023). Enhanced anti-tumor activity and T-cell fitness of 2nd-generation MAGE-A1 TCR T-cells incorporating distinct CD8 co-receptor designs. Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Selck, C., et al. (2023). MAGE-A1 targeting TK-8001 TCR-T cells currently being investigated in the IMAG1NE Phase 1/2 clinical trial demonstrate broad in vitro and in vivo anti-tumor activity and are superior to human-derived MAGE-A1 TCRs. International Society for Cell & Gene Therapy (ISCT) Annual Meeting.
Plewa N, Poncette L, Blankenstein T. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy. J Immunother Cancer. 2023 Feb;11(2):e006001. doi: 10.1136/jitc-2022-006001. PMID: 36822673; PMCID: PMC9950979.
2022
Leliavski, A., et al. (2022). Generating optimal-affinity T cell receptors targeting the shared neoantigen KRASG12V using the humanized TCR transgenic mouse platform HuTCR. American Association for Cancer Research (AACR) Annual Meeting.
2021
Poncette, L., et al. (2021). The role of CD4 T cells in rejection of solid tumors. Current Opinion in Immunology, 74, 18-24.
2019-2010
Poncette, L., et al. (2019). Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regression. The Journal of Clinical Investigation, 129(1), 324–335.
Chen, X., et al. (2017). Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversity. The Journal of Experimental Medicine, 214(11), 3417–3433.
Obenaus, M., et al. (2015). Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nature Biotechnology, 33(4), 402-409.
Li, L., & Blankenstein, T. (2013). Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast–embryonic stem cell fusion. Nature Protocols, 8(8), 1567-1582.
Li, L-P. (2010). Transgenic mice with a diverse human T cell antigen receptor repertoire. Nature Medicine, 16(9), 1029-1035.